The usefulness of Cu-62 ATSM PET/CT to evaluate the sensitivity to radiotherapy for lung cancer and head and neck cancer

The usefulness of Cu-62 ATSM PET/CT to evaluate the sensitivity to radiotherapy for lung cancer and head and neck cancer - The evaluation of the sensitivity to radiotherapy by Cu-62 ATSM PET/CT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005616

Enrollment

Registered

2011-05-19

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer and head and neck cancer

Interventions

Cu-62 ATSM PET/CT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)non-small cell lung cancer or head and neck cancer (pathologically or cytologically proven) 2)Radiotherapy or chemoradiotherapy is scheduled. 3)Iodine contrast media can be administered 4)Written informed concent was obtained. 5)PS 0-2, no severe complication besides malignancy, no pregnancy 6)AST ULNx2.5, ALT ULNx2.5, T.bil 2.0mg/dl, Serum creatinine 1.5mg/dl

Exclusion criteria

Exclusion criteria: 1) Patient under the psychological condition 2) Patient to whom imaging agents cannot be injected 3) Patient who was judged as unsuitable by the doctor

Design outcomes

Primary

Measure	Time frame
Accumulation of Cu-62 ATSM in the tumor	—

Countries

Japan

Contacts

Public ContactHirofumi Fujii

National Cancer Center Division of Functional Imaging

hifujii@ncc.go.jp04-7134-6831

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026